Daytrana Provides meaningful Effectiveness In Both Boys And Girls With ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) has announced that DAYTRANA™ (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had meaningful efficacy in reducing the symptoms of ADHD in both male and

female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric organization (APA) annual assembly in San Diego. [click link for full article]

Original post by admin